CytoDyn Inc.: 10-Q filed 2014-04-11

Name: CytoDyn Inc.: 10-Q filed 2014-04-11
Creator: CytoDyn Inc.

What CytoDyn Inc. reported in its quarterly report filed 2014-04-11 (fiscal Q3 2014): 26 published measures, 76 facts as tagged in accession 0001193125-14-140296.

This filing

Form: 10-Q (quarterly report)
Filed: 2014-04-11
Fiscal period: fiscal Q3 2014
Accession: 0001193125-14-140296 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CytoDyn Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2014-02-28	11,016,170	USD
At 2013-05-31	4,157,699	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2014-02-28	4,250,774	USD
At 2013-05-31	4,381,615	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2014-02-28	6,765,396	USD
At 2013-05-31	-223,916	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2014-02-28	7,395,349	USD
At 2013-05-31	603,681	USD
At 2013-02-28	412,049	USD
At 2012-05-31	284,991	USD
At 2003-10-31	3,238	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-12-01 to 2014-02-28	-3,274,397	USD	90
2013-06-01 to 2014-02-28	-9,435,541	USD	273
2003-11-01 to 2014-02-28	-41,836,448	USD	3773
2012-12-01 to 2013-02-28	-2,359,107	USD	90
2012-06-01 to 2013-02-28	-7,082,759	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2013-06-01 to 2014-02-28	-5,635,719	USD	273
2003-11-01 to 2014-02-28	-21,038,015	USD	3773
2012-06-01 to 2013-02-28	-2,396,065	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2013-06-01 to 2014-02-28	11,217	USD	273
2003-11-01 to 2014-02-28	35,435	USD	3773
2012-06-01 to 2013-02-28	3,135	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2013-06-01 to 2014-02-28	12,438,604	USD	273
2003-11-01 to 2014-02-28	31,965,561	USD	3773
2012-06-01 to 2013-02-28	6,026,258	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2013-06-01 to 2014-02-28	-11,217	USD	273
2003-11-01 to 2014-02-28	-3,535,435	USD	3773
2012-06-01 to 2013-02-28	-3,503,135	USD	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2014-02-28	10,027	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2013-06-01 to 2014-02-28	784,337	USD	273
2003-11-01 to 2014-02-28	12,952,334	USD	3773
2012-06-01 to 2013-02-28	3,025,777	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2013-12-01 to 2014-02-28	-2,875,567	USD	90
2013-06-01 to 2014-02-28	-5,477,431	USD	273
2003-11-01 to 2014-02-28	-35,765,728	USD	3773
2012-12-01 to 2013-02-28	-1,622,738	USD	90
2012-06-01 to 2013-02-28	-6,078,540	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2014-02-28	7,951,404	USD
At 2013-05-31	840,460	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2014-02-28	2,267,966	USD
At 2013-05-31	3,228,598	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2014-02-28	738,130	USD
At 2013-05-31	1,111,285	USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

Period	Value	Unit	Days
2003-11-01 to 2014-02-28	436,000	USD	3773

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2013-12-01 to 2014-02-28	2,875,567	USD	90
2013-06-01 to 2014-02-28	5,477,431	USD	273
2003-11-01 to 2014-02-28	35,765,728	USD	3773
2012-12-01 to 2013-02-28	1,622,738	USD	90
2012-06-01 to 2013-02-28	6,078,540	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2013-12-01 to 2014-02-28	1,655,914	USD	90
2013-06-01 to 2014-02-28	2,387,866	USD	273
2003-11-01 to 2014-02-28	5,767,199	USD	3773
2012-12-01 to 2013-02-28	33,370	USD	90
2012-06-01 to 2013-02-28	254,825	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2014-02-28	55,568,381	shares
At 2013-05-31	30,798,150	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2014-02-28	19,701,295	USD
At 2013-05-31	17,523,796	USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

Period	Value	Unit	Days
At 2014-02-28	2,231,231	USD
At 2013-05-31	1,481,364	USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2014-02-28	3,054,739	USD
At 2013-05-31	3,317,239	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2014-02-28	50,474	USD
At 2013-05-31	321,884	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2013-12-01 to 2014-02-28	-3,274,397	USD	90
2013-06-01 to 2014-02-28	-9,435,541	USD	273
2003-11-01 to 2014-02-28	-47,935,931	USD	3773
2012-12-01 to 2013-02-28	-2,359,897	USD	90
2012-06-01 to 2013-02-28	-7,084,949	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2013-12-01 to 2014-02-28	915,970	USD	90
2013-06-01 to 2014-02-28	2,255,448	USD	273
2003-11-01 to 2014-02-28	24,922,205	USD	3773
2012-12-01 to 2013-02-28	1,352,515	USD	90
2012-06-01 to 2013-02-28	5,120,807	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2013-06-01 to 2014-02-28	13,642,667	USD	273
2003-11-01 to 2014-02-28	22,608,739	USD	3773

Inspect the source

Entity: CytoDyn Inc. / CIK 0001175680
Captured: 2026-09-20T07:44:48.635Z
SEC response SHA-256: ccd180f98f5bd324896d13ce785229f8b7185dbfcf88932cc316c9c53bdaba90

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001175680.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))